Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17


Prolactin and growth hormone affect metaphase-II chromosomes in aging oocytes via cumulus cells using similar signaling pathways.

Lebedeva IY, Singina GN, Lopukhov AV, Shedova EN, Zinovieva NA.

Front Genet. 2015 Aug 27;6:274. doi: 10.3389/fgene.2015.00274. eCollection 2015.


Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse.

O'Leary KA, Shea MP, Schuler LA.

Adv Exp Med Biol. 2015;846:201-20. doi: 10.1007/978-3-319-12114-7_9.


Mechanisms of transient signaling via short and long prolactin receptor isoforms in female and male sensory neurons.

Belugin S, Diogenes AR, Patil MJ, Ginsburg E, Henry MA, Akopian AN.

J Biol Chem. 2013 Nov 29;288(48):34943-55. doi: 10.1074/jbc.M113.486571. Epub 2013 Oct 18.


Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas.

O'Leary KA, Rugowski DE, Sullivan R, Schuler LA.

Oncogene. 2014 Jun 5;33(23):3075-82. doi: 10.1038/onc.2013.278. Epub 2013 Jul 22.


PAK1 regulates breast cancer cell invasion through secretion of matrix metalloproteinases in response to prolactin and three-dimensional collagen IV.

Rider L, Oladimeji P, Diakonova M.

Mol Endocrinol. 2013 Jul;27(7):1048-64. doi: 10.1210/me.2012-1322. Epub 2013 Jun 6.


Stiff collagen matrices increase tumorigenic prolactin signaling in breast cancer cells.

Barcus CE, Keely PJ, Eliceiri KW, Schuler LA.

J Biol Chem. 2013 May 3;288(18):12722-32. doi: 10.1074/jbc.M112.447631. Epub 2013 Mar 24.


PAK1-Nck regulates cyclin D1 promoter activity in response to prolactin.

Tao J, Oladimeji P, Rider L, Diakonova M.

Mol Endocrinol. 2011 Sep;25(9):1565-78. doi: 10.1210/me.2011-0062. Epub 2011 Jun 30.


Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.

Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H, Schuler LA.

Breast Cancer Res. 2011 Jan 28;13(1):R11. doi: 10.1186/bcr2819.


Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes.

Arendt LM, Evans LC, Rugowski DE, Garcia-Barchino MJ, Rui H, Schuler LA.

J Endocrinol. 2009 Oct;203(1):99-110. doi: 10.1677/JOE-09-0221. Epub 2009 Jul 27.


Complex prolactin crosstalk in breast cancer: new therapeutic implications.

Carver KC, Arendt LM, Schuler LA.

Mol Cell Endocrinol. 2009 Aug 13;307(1-2):1-7. doi: 10.1016/j.mce.2009.03.014. Epub 2009 Apr 1.


Tyrosine phosphorylation of Grb2: role in prolactin/epidermal growth factor cross talk in mammary epithelial cell growth and differentiation.

Haines E, Minoo P, Feng Z, Resalatpanah N, Nie XM, Campiglio M, Alvarez L, Cocolakis E, Ridha M, Di Fulvio M, Gomez-Cambronero J, Lebrun JJ, Ali S.

Mol Cell Biol. 2009 May;29(10):2505-20. doi: 10.1128/MCB.00034-09. Epub 2009 Mar 9.


Prolactin-growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERalpha expression.

Arendt LM, Grafwallner-Huseth TL, Schuler LA.

Am J Pathol. 2009 Mar;174(3):1065-74. doi: 10.2353/ajpath.2009.080719. Epub 2009 Jan 29.


Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity.

Howell SJ, Anderson E, Hunter T, Farnie G, Clarke RB.

Breast Cancer Res. 2008;10(4):R68. doi: 10.1186/bcr2129. Epub 2008 Aug 5.


Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell context.

Gutzman JH, Rugowski DE, Nikolai SE, Schuler LA.

Oncogene. 2007 Sep 20;26(43):6341-8. Epub 2007 Apr 16.


Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1/2-mediated signals to c-fos.

Gutzman JH, Nikolai SE, Rugowski DE, Watters JJ, Schuler LA.

Mol Endocrinol. 2005 Jul;19(7):1765-78. Epub 2005 Mar 3.

Supplemental Content

Support Center